Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of two intravenous methylprednisolone doses for acute dysthyroid optic neuropathy
2013-001196-20Phase 4Active
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methylprednisolone in dysthyroid optic neuropathy (DON) and Graves' ophthalmopathy (TED) (2 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoints: Adequate recovery of visual function at 1 month and Adequate recovery of visual function at 3 months. Started Aug 2013; status: active.
02
Drugs
methylprednisolone
03
Conditions
dysthyroid optic neuropathy (DON)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2013-001196-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001196-20.